See more : BetterU Education Corp. (BTTUF) Income Statement Analysis – Financial Results
Complete financial analysis of IN8bio, Inc. (INAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IN8bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Recharge Acquisition Corp. (RCHG) Income Statement Analysis – Financial Results
- Protean eGov Technologies Limi (PROTEAN.BO) Income Statement Analysis – Financial Results
- Avadel Pharmaceuticals plc (AVDL) Income Statement Analysis – Financial Results
- Metal Bank Limited (MBK.AX) Income Statement Analysis – Financial Results
- Sumitomo Rubber Industries, Ltd. (5110.T) Income Statement Analysis – Financial Results
IN8bio, Inc. (INAB)
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.50M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| Gross Profit | -2.50M | -1.10M | -251.00K | -96.00K | -96.00K | -96.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.83M | 14.06M | 7.35M | 5.38M | 2.36M | 581.00K |
| General & Administrative | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -63.00K |
| Operating Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Cost & Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K |
| Depreciation & Amortization | 1.83M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| EBITDA | -28.50M | -27.42M | -14.40M | -8.47M | -5.04M | -1.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.34M | -28.52M | -14.65M | -8.56M | -5.13M | -2.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 330.00K | 0.00 | 0.00 | 0.00 | 0.00 | -77.00K |
| Income Before Tax | -30.01M | -28.52M | -14.65M | -8.56M | -5.13M | -2.08M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.10M | 551.44K | -118.30K | -68.00K | -63.00K |
| Net Income | -30.01M | -27.42M | -14.65M | -8.56M | -5.13M | -2.08M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| EPS Diluted | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| Weighted Avg Shares Out | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
| Weighted Avg Shares Out (Dil) | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference
IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
Source: https://incomestatements.info
Category: Stock Reports